Incyte data positive, says Oppenheimer After Incyte reported results for ruxolitinib in pancreatic cancer, Oppenheimer thinks the data supports the evaluation of ruxolitinib in a wide range of tumor types. Following the results of an IDO + ipilimumab proof-of-concept study in melanoma, Oppenheimer finds the results encouraging. The firm keeps a $75 price target on the shares and reiterates an Outperform rating.
News For INCY From The Last 14 Days
Check below for free stories on INCY the last two weeks.